Anti-C1s antibodies and uses thereof
OwnerBuxin Chen, Lei Huang +1inventors
InventorsBuxin Chen, Lei Huang, Xin Du
Life of this patent
Estimating the term…
Abstract
Antibodies and antigen-binding fragments thereof that bind C1s and inhibit C1s activity and modulate the activity of at least one component in the classical pathway (CP) of complement activation, and methods for treating complement-mediated disorders using anti-C1s antibodies and fragments, are provided.
Claims22
A recombinant anti-C1s antibody or an antigen-binding fragment thereof that is capable of specifically binding to human C1s and inhibiting C1s, comprising a heavy chain variable region (VH) comprising three heavy chain complementarity determining regions (HC CDRs) and a light chain variable region (VL) comprising three light chain complementarity determining regions (LC CDRs), selected from:
- (a) the VH comprising an HC CDR1 having the amino acid sequence GFTFSNYFMN (SEQ ID NO:
- 129), an HC CDR2 having the amino acid sequence EIRLKFTNYATHYA(E/D)SV(EX)G (SEQ ID NO:
- 130), and an HC CDR3 having the amino acid sequence DYGSRN(G/A)YFDY (SEQ ID NO:
- 131), and the VL comprising an LC CDR1 having the amino acid sequence RSSKSLLHSNGNTFLY (SEQ ID NO:
- 132), an LC CDR2 having the amino acid sequence RMSNLAS (SEQ ID NO:
- 133), and an LC CDR3 having the amino acid sequence MQHLEYPYT (SEQ ID NO:
- 134), and
- (b) the VH comprising an HC CDR1 having the amino acid sequence GFNIKEYYMH (SEQ ID NO:
- 135), an HC CDR2 having the amino acid sequence WIDPEN(G/A)D(T/A)IY(D/A)(P/Q)KFQG (SEQ ID NO:
- 136), and an HC CDR3 having the amino acid sequence SRLFFAY (SEQ ID NO:
- 137), and the VL comprising an LC CDR1 having the amino acid sequence ASQDVRTA(V/L)D (SEQ ID NO:
- 138), an LC CDR2 comprising the amino acid sequence SASYRY(T/S) (SEQ ID NO:
- 139), and LC CDR3 comprising the amino acid sequence QQQYTTPYT (SEQ ID NO:
- 140).
Dependencies are inferred from the claim text.